Aim: The objectives were to determine the frequency of in utero fetal death (IUFD) related to placental disorders and to assess the frequency of antiphospholipid antibodies syndrome (APS) among women referred to the internal medicine department. Results: IUFD resulted from placental disorders in 36/53 (68%) patients, and remained unexplained in 11 cases (20.8%). Among the 36 patients with placental disorders, APS was diagnosed in five (13.9%) cases, and four (11.1%) patients were considered as having 'non-criteria' APS. History of thrombosis (P = 0.001) and placental infarcts (P = 0.047) were significantly associated with APS.
INTRODUCTION
There is currently no international consensus on the gestational age threshold which defines in utero fetal death (IUFD). The French National College of Gynecologists and Obstetricians (CNGOF) defines IUFD as a spontaneous cessation of fetal cardiac activity occurring before or during labor, after 14 weeks of amenorrhea, 1 whereas the threshold of either 22 or 28 weeks or more is commonly used in many countries. 2, 3 Bukowski et al. 4 showed that obstetric complications, placental disease, genetic abnormality and infections, were involved in, respectively, 29%, 26%, 13% and 13% of IUFD, then followed by cord abnormalities (10.4%), hypertensive disorders (9.2%) and maternal complications (7.8%). IUFD were considered idiopathic in 24% of cases.
The objectives of IUFD investigations are to identify the cause, to prepare for future pregnancies, and to detect a maternal pathology requiring specific care, such as antiphospholipid antibodies syndrome (APS). 1 APS diagnosis requires the presence of clinical and biological criteria meeting the Sydney classification criteria. 5 However, many patients, while fulfilling the clinical criteria, cannot be classified as having APS either because of non-persistent positivity of conventional antibodies, or because of the detection of other antibodies that have currently not been validated (e.g., anti-prothrombin): in those cases, the appellation of 'non-criteria' APS is sometimes used. 6, 7 
Study objectives
The objectives of our study were to bring to light the internist's role in the diagnosis of IUFD by: (i) analyzing the final etiologies diagnosed, on which depend the treatments that will be proposed for future pregnancies; (ii) evaluating the prevalence of IUFD consecutive to placental vascular disorders; and (iii) assessing the prevalence of APS among these patients and comparing their clinical and pathological features to non-APS patients, in order to find out relevant factors that support APS testing.
MATERIAL AND METHODS
All women who consulted in the internal medicine department of Rennes University hospital, a French tertiary care center, after IUFD (defined as death at 14 weeks of gestation or later according to the CNGOF) were retrospectively included between 1 January, 2007 and 31 December, 2014. All cases of IUFD were reviewed by four specialists (a pediatrician, a pathologist specializing in fetopathology, an obstetrician and an internist) and the main cause of death was determined through consensual agreement.
According to the Amsterdam Placental Workshop Group Consensus Statement, 8 the following histological features were recorded from the pathological records: placental infarcts, retroplacental hematoma, hypotrophia, decidual arteriopathy, fetal vascular malperfusion, thrombosis, villitis, intervillitis and cord abnormalities. IUFD were classified as placenta-related if the lesions observed were deemed sufficient to lead to fetal death.
All APL determinations were performed in our university laboratory. APS research included testing for the presence of lupus anticoagulant (LA), immunoglobulin (Ig)G/IgM anticardiolipin antibodies (ACL), IgG/IgM anti-b2 glycoprotein I (anti-b2GPI) antibodies, and antiprothrombin antibodies. LA was detected using diluted Russell's viper venom and diluted activated partial thromboplastin time in accordance with International Society on Thrombosis and Haematosis recommendations. ACL, anti-b2GPI and antiprothrombin antibodies were tested using colored microspherebased flow cytometric assay (FIDIS APS, Theradiag, Croissy Beaubourg, France) and was performed according to the manufacturer's recommendations. The cut-off values were > 10 UA/mL for anti-B2GPI and anti-prothrombin antibodies. The cut-off value for ACL was > 40 GPL or MPL. The positive thresholds of the FIDIS APS assay were established by 99th percentile of the values obtained by the manufacturer for a normal population (400 samples from blood donors). Patient were categorized into three groups: an APS group, in which were included patients who presented a persistent positivity of at least one conventional APL according to Sydney criteria, a non-criteria APS group in which were included the patients who presented either an intermittent positivity of conventional APL or antiprothrombin antibodies positivity, and a non-APS group, in which were included the patients who presented a non-significant positivity of APS or tested negative. Clinical and pathological characteristics of patients with APS, noncriteria APS and no APS were compared. Patients with APS were classified in the 'maternal cause' category according to the Causes of Death and Associated Conditions (CODAC) classification, 9 and they were also considered as placenta-related IUFD if their placentas exhibited significant lesions.
Statistical methods
Categorical variables associations were analyzed by conducting a Chi-square or Fisher exact test. Quantitative data were analyzed by conducting Student or MannWhitney U-test. We performed all tests with a significance level of P < 0.05. Statistical analyses were performed using SPSS 20.0 software (IBM, Armonk, NY, USA).
This study was approved by the ethics committee of Rennes University Hospital (authorization no. 16.130).
RESULTS

Patients characteristics
Over the study period, 53 patients consulted in internal medicine for IUFD, all of whom were referred by their obstetrician. Twenty-two patients (42%) were primigravida, five patients (9%) had a history of IUFD, nine (17%) had a history of miscarriage, two had an antecedent of pre-eclampsia, two an antecedent of HELLP syndrome (hemolysis, elevated liver enzymes and low platelet count). A history of severe fetal growth restriction (< 5 percentile) was mentioned in two cases. One patient suffered from chronic hypertension, no patients had diabetes mellitus and none had renal disease. Nine patients (13%) were overweight or obese. Three patients were known to have APS, revealed in all cases by venous thrombo-embolism (VTE). APS was considered as primary in all cases as none of our patients had associated connective tissue disease. The patients' mean age at the time of IUFD was of 30 AE 4.5 years (extremes: 19-42). The mean term was 29.2 weeks of amenorrhea AE7.9 (extremes 15-40). There were no multiple pregnancies. Distribution of IUFD according to gestational age is shown in Figure 1 .
At the time of IUFD, 7/53 (13%) patients were receiving anticoagulant therapy or antiplatelet agents: four were treated with low-dose aspirin (LDA), because of previous fetal loss in three cases, and of severe fetal growth restriction in one case. The three patients with known APS were receiving LDA combined with lowmolecular weight heparin (LMWH).
Biology APL (LA, ACL, anti-b2GPI or anti-prothrombin antibodies) were tested in 49/53 patients (90%), and were positive in nine (17%) cases. The detailed results of the nine positive APL patients are presented in Table 1 .
Among the nine APL positive patients, eight underwent repeat testing 12 weeks later. Among them, five still tested positive: they were classified as having definite APS. The four other patients presented 'non-criteria' APS: one of them was tested positive for LA without confirmation 12 weeks apart; the three others presented low titers or were negative for conventional APL, but tested positive for anti-prothrombin antibodies (patients 5, 6 and 9). Patient 9 also tested positive for antib2GPI IgG which was not confirmed 12 weeks apart.
Pathological findings
A placental histological analysis was performed in 49/ 53 cases (92%). Anomalies were found in 40/49 (81%) of the placentas.
Vascular disorders were noted in 33/49 (73%) placentas. Retroplacental hematoma was found in 10 cases, infarcts in 19 cases. Thromboses were observed in two cases, decidual arteriopathy was found in three cases. Fetal vascular malperfusion was observed in seven patients, only one of whom had gestational diabetes. Inflammatory disorders were found in three cases: two cases of villitis and one case of intervillitis, in all of which TORCH (toxoplasmosis, rubella, cytomegalovirus and herpes virus) screening was negative. IUFD was related to cord anomaly in four cases: cord thrombosis in three cases and tight loops in one case.
All the placentas of the nine APL positive patients (definite and 'non-criteria' APS) were examined: all presented vascular disorders, which associated hypotrophy (constant) with decidual arteriopathy in one case, infarcts in 8/9 cases, retroplacental hematoma in two cases, and thrombi in two cases. In one patient the coexistence of fetal vascular malperfusion was noted.
Results for the primary outcome: final etiologies diagnosed and prevalence of IUFD related to placental disorders
The main causes of IUFD are reported in Table 2 . Etiological categories were extracted from the CODAC classification:
9 six cases issued from maternal causes, including the 5 definite APS patients plus one patient whose IUFD was secondary to severe pre-eclampsia. IUFD of 'non-criteria' (n = 4) and non-APS patients (n = 27) were ruled as having a placental cause. IUFD resulted from placental disorders in 36/53 (68%) patients: placental insufficiency in 33 (62%) cases (including one case of pre-eclampsia), and placental inflammatory disorders in three (6%) cases. None of our patients had isolated gestational hypertension, renal disease or connective tissue disease.
IUFD was caused by fetal anemia in one case which was classified as a fetal cause, by parvovirus B19 infection in one case, and by funicular pathology in four cases.
IUFD remained unexplained in 11/53 (21%) cases, including all the patients whose placenta were not examined.
Results for secondary outcomes: prevalence of APS and clinical/pathological features of APS, non-criteria APS and non-APS patients
The overall prevalence of APS in our cohort was 9% (5/53), but if we consider the patients presenting PVD, it rises to 14% (5/36). The 36 patients who had significant placental disorders were allocated to one of the following groups according to their APS status: definite APS, 'non-criteria' APS and non-APS (in which the patient with pre-eclampsia was included as her placenta exhibited hypotrophia along with massive infarct and retroplacental hematoma).
Only the three patients with known APS had VTE history. Antecedent of VTE (P = 0.001) and placental infarcts (P = 0.047) were significantly associated with the definite APS group, whereas fetal vascular malperfusion or inflammatory disorders (villitis/ intervillitis) were not. Patients with 'non-criteria' APS were not different from non-APS patients regarding VTE history or pathological findings.
There were no differences in mothers' ages, time of pregnancy termination, presence of livedo, history of fetal loss or placental hypotrophia, between the three groups.
DISCUSSION
Fifty-three cases of IUFD were referred to an internist over the study period. In the meantime, 440 cases were registered in our center, meaning that internists were consulted in 12% of cases. Placental disorders were over-represented, as they accounted for 31 (58%) cases, whereas Bukowski et al. showed that they are usually involved in only 23.6% of IUFD. 4 Moreover, no genetic causes were observed, while infectious and fetal causes were rarely found (one case of each), although Bukowski et al. demonstrated that such etiologies are 4, 10, 11 These include the four patients whose placenta was not examined. This emphasizes the crucial importance of performing placental pathological examinations.
In our study, as previously demonstrated, placental examination was highly contributive, 12, 13 since significant histological lesions were noted in 40/49 (81%) cases (including cord abnormalities in four cases).
As for patients with placental abnormalities, only 5/ 36 (14%) were found to have APS meeting the Sydney criteria. 5 Unsurprisingly, history of thrombosis was significantly associated with the diagnosis of definite APS (P = 0.001).
14 Among histological patterns, placental infarcts were associated with APS (P = 0.047), whereas other lesions such as fetal thrombosis or villitis were not: this is consistent with previous studies which showed that infarct is the most common pathological feature encountered in patients with obstetrical APS. 15, 16 These results emphasize the need for APL testing in patients presenting a VTE history or placental infarcts. Diagnosing obstetrical APS is essential since such patients may benefit from the association of aspirin and heparin, which increases the live birth rate for future pregnancies up to 70%. 17, 18 'Non-criteria' APS was discussed in 4/36 (11%) patients, because of either intermittent LA positivity, or isolated anti-prothrombin positivity. In our study, 'non-criteria' APS patients were not different from non-APS patients regarding clinical or pathological features. Notably, they showed neither a larger history of thrombosis, nor more placental infarcts. This finding does not support the relevance of an entity such as 'non-criteria' APS. The best treatment regimen for those patients with 'non-criteria' APS for future pregnancies is still debated, 19, 20 although Mekinian et al. 21 recently showed that they may benefit from the same treatment as patients with definite APS.
Above all, 27/36 (75%) patients did not have APS, although they exhibited significant placental lesions. Placental inflammatory disorders, including villitis and intervillitis were found in three of our patients (8%). Their physiopathology remains unclear in most cases; 22 nevertheless previous studies have shown that such lesions might not be associated with APS. 15, [23] [24] [25] [26] The final question is to find out how to manage the future pregnancies of the 24/36 (67%) APL negative patients who presented an IUFD related to placental vascular disorders. Aspirin is often prescribed, sometimes associated with heparin by analogy with APS patients. Nevertheless, previous studies have failed to demonstrate the validity of such an attitude so far. [27] [28] [29] This situation raises the need for studies aiming at determining the best treatment options in non-APS patients presenting IUFD of placental vascular origin.
CONCLUSION
The investigation of IUFD requires close multi-disciplinary collaboration, in which the internist should play a substantial role. APL testing is a major feature of IUFD exploration, particularly in cases of maternal venous thromboembolism history or in cases of placental infarcts, as both were significantly associated with APS. Notably, most IUFD were found to originate from placental vascular disorders which were not related to APS: further studies are needed to determine the underlying mechanisms, in order to define the best treatment for future pregnancies.
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